Bimatoprost in the treatment of eyelash hypotrichosis

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 349-358

  Law, Simon K ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Bimatoprost; Eyelash; Hypotrichosis; Latisse; Prostaglandin; Prostamide

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; CYCLOOXYGENASE 1; DOXORUBICIN; LATANOPROST; LATISSE; MINOXIDIL; PROSTAGLANDIN DERIVATIVE; PROSTANOID RECEPTOR; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

ABDOMINAL CRAMP; ALOPECIA AREATA; ANGINA PECTORIS; ARTHRALGIA; ASTHENIA; BACKACHE; BLOOD PRESSURE; CLINICAL TRIAL; COMMON COLD; CONJUNCTIVAL HYPEREMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRY EYE; ENOPHTHALMOS; ENZYME ACTIVATION; EYE COLOR; EYE IRRITATION; EYELASH HYPOTRICHOSIS; EYELID ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HAIR FOLLICLE; HAIR GROWTH; HEART RATE; HERPES SIMPLEX KERATITIS; HIRSUTISM; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOTRICHOSIS; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; LIVER FUNCTION TEST; MYALGIA; NONHUMAN; OCULAR PRURITUS; PATIENT EDUCATION; PATIENT MONITORING; PROTEIN INTERACTION; RADIATION EXPOSURE; RETINA MACULA CYSTOID EDEMA; REVIEW; SIDE EFFECT; TACHYCARDIA; TERATOGENICITY; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

EID: 77953374959     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s6480     Document Type: Review

References (94)

1. International society of hair restoration surgery. Eyelash transplantation: Who, Why and How. http://www.ishrs.org/articles/eyelash-transplantation.htm Accessed Nov 30, 2009.
2. Woodson SA. Latisse: empirical discovery yields treatment for sparse eyelashes. Nurs Womens Health. 2009;13:243-248.
3. Pucci N, Novembre E, Lombardi E, et al. Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis. Pediatrics. 2005;115:1542-1555.
4. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124: 544-547.
5. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997;115:1206-1208.
6. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.
7. Noecker RS, Dirks MS, Choplin NT, et al; Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and lantanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
8. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of lantaoprost, bimatoprost, and travaprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
9. Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112:262-266.
10. Liotet S, Riera M, Nguyen H. Les cils. Physiologie, structure, pathologie. Arch Ophthalmol. 1977;37:697-708.
11. Na JI, Kwon OS, Kim BK, et al. Ethnic characteristics of eyelashes: a comparative analysis in Asian and Caucasian females. Br J Dermatol. 2006;155:1170-1176.
12. Montagna W, Ford DM, Histology and cytochemistry of human skin. 3. The eyelid. Arch Dermatol. 1969;100:328-335.
13. Thibaut S, De Becker E, Calsey L, et al. Human eyelash characterization. Br J Dermatol. 2009 Sep 1. [Epub ahead of print].
14. Bartosová L. Biology of hair growth. Curr Probl Dermatol. 1984;12:1-58.
15. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl 1):S185-S202.
16. Katz M, Wheeler KE, Radowsky M, Gordon W. Assessment of rate of hair growth using a simple trichometer. Med Biol Eng Comput. 1979;17:333-336.
17. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000;21:363-392.
18. Elder MJ. Anatomy and physiology of eyelash follicles: relevance to lash ablation procedures. Ophthal Plast Reconstu Surg. 1997;13:21-25.
19. Bläuer M, Vaalasti A, Pauli SL, Ylikomi T, Joensuu T, Tuohimaa P. Location of androgen receptor in human skin. J Invest Dermatol. 1991;97:264-268.
20. Randall VA, Hibberts NA, Thornton MJ, et al. The hair follicle: a paradoxical androgen target organ. Horm Res. 2000;54:243-250.
21. Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45 Suppl 4:S337-S345.
22. Woodward DF, Krauss AH, Chen J, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003;305:772-785.
23. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol. 2008;20 Suppl 1:1-9.
24. Alpini G, Demorrow S. Changes in the endocannabinoid system may give insight into new and effective treatments for cancer. Vitam Horm. 2009;81:469-485.
25. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol. 2006;160:1-24.
26. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandinethanolamides) and their pharmacology. Br J Pharmacol. 2008;153: 410-419.
27. Liang Y, Woodward DF, Guzman VM, et al. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol. 2008;154:1079-1093.
28. Colombe L, Vindios A, Michelet JF, Bernard BA. Prostaglandin metabolism in human hair follicle. Exp Dermatol. 2007;16:762-769.
29. Colombe L, Michelet JF, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol. 2008;17:63-72.
30. Torii E, Segi E, Sugimoto Y, et al. Expression of prostaglandin E92 receptor subtypes in mouse hair follicles. Biochem Biophys Res Comm. 2002;290:696-700.
31. Rosenigk HH Jr. New topical agents for hair growth. Clin Dermatol. 1988;6:119-121.
32. Meyer HC. Alopecia associated with ibuprofen. JAMA. 1979: 242:142.
33. Pillans PI, Woods DJ. Drug-associated alopecia. Int J Dermatol. 1995;34:149-158.
34. Michelet JF, Commo S, Billoni N, Mahe YF, Bernard BA. Activation of ytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108:205-209.
35. Stjernschantz JW. From PGF (2alpha)-isopropyl ester to lantaoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134-1145.
36. Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2a and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005;14:323-328.
37. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macaque: a pilot study. Acta Derm Venereol. 2002;82:7-12.
38. Burnett JW, Harvey VM. Circumscribed palmar or plantar hypokeratosis: report of two additional cases. J Am Acad Dermatol. 2004;51:843-844.
39. Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341:491-497.
40. Demitsu T, Manabe M, Harima N, Sugiyama T, Yoneda K, Yamada N. Hypertrichosis induced by lantanoprost. J Am Acad Dermatol. 2001;44:721-723.
41. Inouye K, Wakakura M, Inoue J, Matsuo H, Hara T, Tomita G. Adverse reaction after use of latanoprost in Japanese glaucoma patients. Nippon Ganka Gakkai Zasshi. 2006;110:581-587.
42. Elgin U, Batman A, Becker N, Iihan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol. 2006;16:247-250.
43. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
44. Sherwood M, Brandt J; Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45 Suppl 4:S361-S368.
45. Brandt JD, VanDenburgh AM, Chen K, et al. Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023-1031.
46. Food and Drug Administration, Division of Anti-infective and Ophthalmology Products Advisory Committee. Briefing information: bimatoprost ophthalmic solution for the treatment of hypotrichosis of the eyelashes. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-03-FDA.pdf. Accessed Nov 30, 2009.
47. Chen CS, Wells J, Craig JE. Topical prostaglandin F2 analog induced poliosis. Am J Ophthalmol. 2004;137:965-966.
48. Zaheri S. Hughes B. Successful use of bimatoprost in the treatment of alopecia of the eyelashes. Clin Exp Dermatol. 2009 Nov 19. [Epub ahead of print].
49. Ochoa BE, Sah D, Wang G, Stamper R, Price VH. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol. 2009;61:530-532.
50. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol. 2000;118: 718-719.
51. Mehta JS, Raman J, Gupta N, Thoung D. Cutaneous latanoprost in the treatment of alopecia areata. Eye. 2003;17:444-446.
52. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. J Am Acad Dermatol. 2009;60:705-706.
53. Feletti F, Vincenzi C, Pazzaglia M, Tosti A. Periocular pigmentation associated with use of travoprost for the treatment of alopecia areata of the eyelashes. J Eur Acad Dermatol Venereol. 2007;21:421-423.
54. Geng L, Hanson WR, Malkinson FD. Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation. Int J Radiat Biol. 1992;61:533-537.
55. Hanson WR, Pelka AE, Nelson AK, Malkinson FD. Subcutaneous or topical administration of 16, 16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice. Int J Radiat Oncol Biol Phys. 1992;23:333-337.
56. Malkinson FD, Geng L, Hanson WR. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin. J Invest Dermatol. 1993;101:135S-137S.
57. Cracknell KP, Grierson I, Hogg P, Appleton P, Pfeiffer N. Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies. Exp Eye Res. 2003;77:721-730.
58. Cracknell KP, Farnell DJ, Grierson I. Monte Carlo simulation of latanoprost induced iris darkening. Comput Methods Programs Biomed. 2007;87:93-103.
59. Arranz-Marquez E, Teus MA. Effect of age on the development of a latanoprost-induced increase in iris pigmentation. Ophthalmology. 2007;114:1255-1258.
60. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl 2):S129-S138.
61. Stewart WC, Kolker AE, Stewart JA, et al. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135:314-320.
62. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol. 2001;119:300-301.
63. Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol. 2005;123:1541-1546.
64. Centofanti M, Oddone F, Chimenti S, Tanga L, Citarella L, Manni G. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Am J Ophthalmol. 2006;142:1059-1060.
65. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574-577.
66. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprostcan bimatoprost cause enophthalmos? Klin Monbl Augenheilkd. 2008;225:443-445.
67. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24:302-307.
68. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53:176-179.
69. Packer M, Fine IH, Hoffman RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003;29:2242-2243.
70. Parentin F. Granulomatous anterior uveitis associated with bimatoprost: a case report. Ocul Immunol Inflamm. 2003;11:67-71.
71. Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668-672.
72. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263.
73. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998;126:37-41.
74. Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol. 2002;133:401-403.
75. Kothari MT, Mehta BK, Asher NS, Kothari KJ. Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use. Indian J Ophthalmol. 2006;54:47-48.
76. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127:602-604.
77. Morales J, Shihab ZM, Brown SM, et al. Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol. 2001;132:114-116.
78. Kaufman HE, Varnell ED, Thompson HW. Latanprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol. 1999;127:531-536.
79. Gordon YJ, Yates KA, Mah FS, et al. The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models. J Ocul Pharmacol Ther. 2003;19:233-245.
80. Hempstead N, Hempstead RW. Unilateral trichomegaly induced by bimatoprost ophthalmic solution. J Drugs Dermatol. 2004;3: 571-572.
81. Herane MI, Urbina F. Acquired trichomegaly of the eyelashes, and hypertrichosis induced by bimatoprost. J Eur Acad Dermatol Venereol. 2004;18:644-645.
82. Hart J. Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol. 2004;137:756-757.
83. Bearden W, Anderson R. Trichiasis associated with prostaglandin analog use. Ophthal Plast Reconstr Surg. 2004;20(4):320-322.
84. Casson RJ, Selva D. Lash ptosis caused by latanoprost. Am J Ophthalmol. 2005;139:932-933.
85. Doshi M, Edward DP, Osmanovic S. Clinical course of bimatoprost- induced periocular skin changes in Caucasians. Ophthalmology. 2006;113:1961-1967.
86. Herndon LW, Williams RD, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensice lipid use in African Americans. Am J Ophthalmol. 2003;135:713-715.
87. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123-4128.
88. Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004;137:966-968.
89. Laibovitz RA, VanDenburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001;119:994-1000.
90. Dubiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(Suppl 4):S353-S360.
91. Lee YC. Abdominal cramp as an adverse effect of travoprost. Am J Ophthalmol. 2005;139:202-203.
92. Mitra M, Chang B, James T. Drug points. Exacerbation of angina associated with latanoprost. BMJ. 2001;323:783.
93. Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother. 1998;32:504-505.
94. De Santis M, Lucchese A, Carducci B, et al. Latanoprost exposure in pregnancy. Am J Ophthalmol. 2004;138:305-306.